RestorGenex Announces Presentation of Prostate Cancer Data

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
RestorGenex Announces Presentation of Prostate Cancer Data on RES-529, a Dual TORC1/TORC2 Inhibitor

BUFFALO GROVE, Ill., June 19, 2015 (GLOBE NEWSWIRE) -- RestorGenex Corporation (OTC:RESX), a specialty biopharmaceutical company focused on developing products for oncology, ophthalmology and dermatology, today announced that in vitro and in vivo data will be presented on the use of RES-529 in a prostate cancer cell model. The data titled, "RES-529, A Dual TORC1/TORC2 Inhibitor, Potentiates the In Vitro and In Vivo Efficacy of Hormone Manipulations in the 22RV1 Prostate Cancer Cell Model" will be presented by Claudio Festuccia, Department of Clinical Sciences and Applied Biotechnology, Università degli Studi dell'Aquila, at the XXVth National Congress of the Italian Society of Uro-Oncology (SIUrO), on June 22, 2015 in Rome, Italy.

"Dr. Festuccia has studied TORC1 and TORC2 inhibition extensively in various cancer models. His work on RES-529 has provided RestorGenex with key compound information that has been integral to our research and development planning. The reported study investigated the role of TORC1 and TORC2 in proliferation and apoptosis induced by hormone manipulation in both androgen sensitive and castration resistant prostate cancer models. In addition, Professor Festuccia and his team evaluated the potential for combination treatment of RES-529 induced TORC1/TORC2 inhibition with hormonal therapy in both in vitro and in vivo models," stated Mark Weinberg, MD, MBA, senior vice president of clinical development for RestorGenex. "We look forward to Professor Festuccia's presentation and conclusions at the close of the Congress."

Stephen M. Simes, chief executive officer of RestorGenex added, "Carcinoma of the prostate is an increasing healthcare problem globally. The need for superior therapeutic regimens and the development of novel treatments to improve the poor outcomes of patients with castration-resistant prostate cancer remains. RestorGenex is encouraged by the ongoing research of RES-529 in various cancer types including prostate cancer, glioblastoma, breast cancer and lung cancer."

About RestorGenex Corporation

RestorGenex is a specialty biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies. For additional information please see:  www.restorgenex.com .

Forward Looking Statements

Certain statements in this release are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the potential benefits of RES-529 and other statements that are not historical in nature, particularly those that utilize terminology such as "will," "potential," "look forward," "could," "plans," "anticipates," "expects," "may," "future," "continue," "show promise," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Risks and uncertainties may cause RestorGenex's actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular risks and uncertainties include, among others, uncertainties involved in clinical testing, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, RestorGenex's ability to license out its existing products and technologies and license in additional products and technologies and the terms of such licenses; and other risks and uncertainties described in RestorGenex's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K for the fiscal year ended December 31, 2014 and subsequent quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2015. All forward-looking statements in this release speak only as of the date of this release and are based on RestorGenex's current beliefs and expectations. RestorGenex undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

The Trout Group LLC Marcy Nanus, 646-378-2927 PCG Advisory Group Stephanie Prince, 646-762-4518

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 83

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 38

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
IP Lawyer Chris Henry Returns to Latham: A Game Changer

Updated Category News Views 106

Welcome Home, Chris Henry! Folks, here's a headline that's making waves in the IP litigation water: Chris Henry has returned to Latham & Watkins, taking his place as a heavyweight partner in their Boston office. Now, if you're not deeply entangled in the world of high-stakes intellectual property (IP) disputes, you might shrug. But for tech companies embroiled in patent...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 78

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 122

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 101

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 161

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 142

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Pinot's Palette Expands with New La Quinta Studio

Updated Category News Views 79

Canvas and Cabernet in Coachella Valley Grab your brushes and wine glasses; Pinot's Palette is branching out to La Quinta. As of November 27, locals and visitors alike can find their artistic flair at 47120 Dune Palms Road. This move isn’t just another business expansion—it's about blending community spirit with creativity, backed by the experienced entrepreneurs...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 104

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking Passive Income with JDH AI and XRP Earnings

Updated Category News Views 148

Harnessing AI for Earning XRP The demand for artificial intelligence is surging, and its integration with cryptocurrency platforms is paving the way for innovative earning opportunities. JDH AI symbolizes this transformative shift, bridging cutting-edge AI technology with blockchain to offer users a streamlined approach for generating passive income. Innovative Solutions...

Continue Reading
AgVault Innovates Ethanol Production with Cutting-Edge Solutions

Updated Category News Views 271

AgVault's Innovative Approach to Ethanol Production With the ethanol production landscape continually evolving, AgVault is at the forefront of transforming the industry with a pioneering fermentation technology. This innovative approach aims to significantly enhance profitability in existing ethanol facilities, where traditional efficiency gains have become increasingly...

Continue Reading
Groundbreaking Launch of JFF's Innovative Brand Studio Initiative

Updated Category News Views 178

Launch of JFF's Groundbreaking Brand Studio JFF has embarked on an exciting journey by unveiling its new Brand Studio, a revolutionary initiative that aims to transform branding efforts for organizations. This initiative represents the culmination of innovative thinking, aimed at creating strong connections between brands and their audiences. Innovative Approach to...

Continue Reading
Discover the Exciting New Route for the 2025 Marathon

Updated Category News Views 180

Introduced New Route Maps for the 2025 Zeigler Kalamazoo Marathon The anticipation is building for the 2025 Zeigler Kalamazoo Marathon as new route maps have been unveiled for all participants including the Marathon, Half Marathon, 5K, 10K, and PNC Kids' Run. This year, the event is set to take place in a different venue: the scenic Bronson Park. This transition to a new...

Continue Reading
Nurses at Newton-Wellesley Hospital Plan Strike Authorization Vote

Updated Category News Views 59

Nurses at Newton-Wellesley Hospital Prepare for Strike Vote The registered nurses at Newton-Wellesley Hospital, advocating for patient care and fair working conditions, are gearing up for a critical strike authorization vote. This move aims to confront the increasing health insurance costs imposed by Mass General Brigham. Strike Authorization Vote Details The vote is...

Continue Reading